{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:10:40Z","timestamp":1791526240890,"version":"4.3.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["redjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.ijrobp.2017.10.015","type":"journal-article","created":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T07:21:03Z","timestamp":1509088863000},"page":"1133-1145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Comparison of 36\u00a0Gy, 20\u00a0Gy, or No Radiation Therapy After 6 Cycles of EBVP Chemotherapy and Complete Remission in Early-Stage Hodgkin Lymphoma Without Risk Factors: Results of the EORT-GELA H9-F Intergroup Randomized Trial"],"prefix":"10.1016","volume":"100","author":[{"given":"Jos\u00e9","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Ferm\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evert M.","family":"Noordijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th\u00e9odore","family":"Girinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Gaillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieternella J.","family":"Lugtenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marnix L.M.","family":"Lybeert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aspasia","family":"Stamatoullas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Beijert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"H\u00e9lias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2736-0503","authenticated-orcid":false,"given":"Houchingue","family":"Eghbali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Gabarre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W.M.","family":"van der Maazen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Jaubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krimo","family":"Bouabdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Boulat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith M.","family":"Roesink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Christian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Bordessoule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Tertian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2703-7922","authenticated-orcid":false,"given":"Hugo","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrej","family":"Vranovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Quittet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Tirelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9e","family":"Audouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berthe M.P.","family":"Aleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9357-6476","authenticated-orcid":false,"given":"Michel","family":"Henry-Amar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2017.10.015_bib1","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1200\/JCO.2006.07.0482","article-title":"Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended field radiotherapy is superior to radiotherapy alone in early favourable Hodgkin's lymphoma: Final results of the GHSG HD7 trial","volume":"25","author":"Engert","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.10.015_bib2","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa064601","article-title":"Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease","volume":"357","author":"Ferme","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2017.10.015_bib3","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1200\/JCO.2005.05.2746","article-title":"Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: Long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials","volume":"24","author":"Noordijk","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.10.015_bib4","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/1097-0142(19930915)72:6<2049::AID-CNCR2820720642>3.0.CO;2-V","article-title":"Treatment of pediatric Hodgkin disease tailored to stage, mediastinal mass and age. An Italian (AIEOP) multicenter study on 215 patients","volume":"72","author":"Vecchi","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2017.10.015_bib5","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1200\/JCO.1994.12.10.2160","article-title":"ABVD\/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin's disease: The Stanford experience","volume":"12","author":"Hunger","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.10.015_bib6","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJM199603213341201","article-title":"Breast cancer and other second neoplasms after childhood Hodgkin's disease","volume":"334","author":"Bhatia","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2017.10.015_bib7","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1200\/JCO.1997.15.6.2275","article-title":"Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate stage Hodgkin's disease","volume":"15","author":"Loeffler","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.10.015_bib8","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk","volume":"175","author":"van Nimwegen","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ijrobp.2017.10.015_bib9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2013-10-532184","article-title":"Risk of multiple primary malignancies following treatment of Hodgkin lymphoma","volume":"124","author":"van Eggermond","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2017.10.015_bib10","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/S1470-2045(09)70258-X","article-title":"Quality of life after successful treatment of early-stage Hodgkin lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial","volume":"10","author":"Heutte","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2017.10.015_bib11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1200\/JCO.2004.01.021","article-title":"Consolidation radiation after complete remission in Hodgkin's disease following 6\u00a0cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: Is there a need?","volume":"22","author":"Laskar","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.10.015_bib12","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1200\/JCO.2002.12.007","article-title":"Randomized comparison of low dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy","volume":"20","author":"Nachman","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.10.015_bib13","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1182\/blood-2004-04-1311","article-title":"Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II and IIIA non-bulky Hodgkin disease","volume":"104","author":"Straus","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2017.10.015_bib14","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1200\/JCO.2005.01.911","article-title":"Chemotherapy alone for early Hodgkin's lymphoma: An emerging option","volume":"23","author":"Canellos","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.10.015_bib15","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1200\/JCO.2005.04.4396","article-title":"Don't throw out the baby with the bathwater: On optimizing cure and reducing toxicity in Hodgkin's lymphoma","volume":"24","author":"Yahalom","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.10.015_bib16","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1002\/1097-0142(19801201)46:11<2403::AID-CNCR2820461116>3.0.CO;2-9","article-title":"Prognostic significance of mediastinal involvement in Hodgkin's disease treated with curative radiotherapy","volume":"46","author":"Lee","year":"1980","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2017.10.015_bib17","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","article-title":"Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting","volume":"7","author":"Lister","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.10.015_bib18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/sim.1425","article-title":"Noninferiority trials: Design concepts and issues\u2014The encounters of academic consultants in statistics","volume":"22","author":"D\u2019Agostino","year":"2003","journal-title":"Stat Med"},{"key":"10.1016\/j.ijrobp.2017.10.015_bib19","series-title":"The Design and Analysis of Clinical Experiments","first-page":"92","article-title":"Special Cases of the Parallel Groups Study: Several Treatments Versus a Control","author":"Fleiss","year":"1986"},{"key":"10.1016\/j.ijrobp.2017.10.015_bib20","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2307\/2530109","article-title":"Predictive probability for early termination plans for phase II clinical trials","volume":"35","author":"Herson","year":"1979","journal-title":"Biometrics"},{"key":"10.1016\/j.ijrobp.2017.10.015_bib21","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stages Hodgkin's lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2017.10.015_bib22","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3324\/haematol.2009.015644","article-title":"Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: A systematic review","volume":"95","author":"Herbst","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.ijrobp.2017.10.015_bib23","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.radonc.2006.05.015","article-title":"Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines","volume":"79","author":"Girinsky","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2017.10.015_bib24","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: Field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.10.015_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2005.10.018","article-title":"Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease","volume":"78","author":"Shahidi","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2017.10.015_bib26","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1182\/blood.V126.23.578.578","article-title":"Response-adapted chemotherapy or chemotherapy\/radiation therapy based on PET for non-bulky stage I and II Hodgkin lymphoma (HL) (CALGB\/Alliance 50604)","volume":"126","author":"Straus","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2017.10.015_bib27","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: Final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.10.015_bib28","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2017.10.015_bib29","unstructured":"HD16 for early stages\u2014Treatment optimization trial in the first-line treatment of early stage Hodgkin lymphoma; treatment stratification by means of FDG-PET. Available at: https:\/\/clinicaltrials.gov\/ct\/show\/NCT00736320. Accessed August 22,\u00a02017."}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301617339846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301617339846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T16:25:26Z","timestamp":1603211126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301617339846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0360301617339846"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2017.10.015","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of 36\u00a0Gy, 20\u00a0Gy, or No Radiation Therapy After 6 Cycles of EBVP Chemotherapy and Complete Remission in Early-Stage Hodgkin Lymphoma Without Risk Factors: Results of the EORT-GELA H9-F Intergroup Randomized Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2017.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}